EPFL spin-off "Innovative Medicines for Tuberculosis" (iM4TB) has been awarded nearly USD 750,000 by the Bill & Melinda Gates Foundation to develop a breakthrough drug against tuberculosis. Tuberculosis (TB) affects a third of the world's population. In 2013, an estimated nine million people developed TB, of whom 360,000 were HIV-positive, while the disease or complications from it proved fatal for another 1.5 million. Consequently, TB now ranks as the 8th cause of death in emerging countries. EPFL spin-off Innovative Medicines for Tuberculosis (iM4TB), is answering the challenge with a promising new drug. Moving onto early clinical trials, the work has been bolstered by a grant from the Bill & Melinda Gates Foundation. Founded in 2013, iM4TB is a not-for-profit foundation based in EPFL's innovation park, Lausanne, Switzerland, and supported by the EU's Seventh Framework Programme consortium More Medicines for Tuberculosis.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
Your Benefits
- Access to all content
- Receive newsmails for news and jobs
- Post ads
